Back to Search
Start Over
Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: a Spanish Cooperative Group for the Treatment of Digestive Tumors study.
- Source :
-
The oncologist [Oncologist] 2012; Vol. 17 (7), pp. 947-55. Date of Electronic Publication: 2012 May 29. - Publication Year :
- 2012
-
Abstract
- Background: The Maintenance in Colorectal Cancer trial was a phase III study to assess maintenance therapy with single-agent bevacizumab versus bevacizumab plus chemotherapy in patients with metastatic colorectal cancer. An ancillary study was conducted to evaluate the circulating tumor cell (CTC) count as a prognostic and/or predictive marker for efficacy endpoints.<br />Patients and Methods: One hundred eighty patients were included. Blood samples were obtained at baseline and after three cycles. CTC enumeration was carried out using the CellSearch® System (Veridex LLC, Raritan, NJ). Computed tomography scans were performed at cycle 3 and 6 and every 12 weeks thereafter for tumor response assessment.<br />Results: The median progression-free survival (PFS) interval for patients with a CTC count ≥3 at baseline was 7.8 months, versus the 12.0 months achieved by patients with a CTC count <3 (p = .0002). The median overall survival (OS) time was 17.7 months for patients with a CTC count ≥3, compared with 25.1 months for patients with a lower count (p = .0059). After three cycles, the median PFS interval for patients with a low CTC count was 10.8 months, significantly longer than the 7.5 months for patients with a high CTC count (p = .005). The median OS time for patients with a CTC count <3 was significantly longer than for patients with a CTC count ≥3, 25.1 months versus 16.2 months, respectively (p = .0095).<br />Conclusions: The CTC count is a strong prognostic factor for PFS and OS outcomes in metastatic colorectal cancer patients.
- Subjects :
- Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal, Humanized administration & dosage
Antibodies, Monoclonal, Humanized adverse effects
Bevacizumab
Capecitabine
Colorectal Neoplasms pathology
Deoxycytidine administration & dosage
Deoxycytidine analogs & derivatives
Disease-Free Survival
Female
Fluorouracil administration & dosage
Fluorouracil analogs & derivatives
Humans
Male
Middle Aged
Neoplasm Metastasis
Organoplatinum Compounds administration & dosage
Oxaliplatin
Prognosis
Survival Analysis
Treatment Outcome
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Colorectal Neoplasms blood
Colorectal Neoplasms drug therapy
Neoplastic Cells, Circulating pathology
Subjects
Details
- Language :
- English
- ISSN :
- 1549-490X
- Volume :
- 17
- Issue :
- 7
- Database :
- MEDLINE
- Journal :
- The oncologist
- Publication Type :
- Academic Journal
- Accession number :
- 22643538
- Full Text :
- https://doi.org/10.1634/theoncologist.2012-0048